title: [Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives].
abstract: The identification of fusion genes provides new insights into the initial mechanisms of molecular events implicated in the prostate cancer tumorigenesis. The presence of TEMPRSS2-ETS fusion in up to half of all human prostate cancer makes it perhaps the most common genetic rearrangement in human epithelial tumors. Some data suggest that TMPRSS2-ERG fusion prostate cancers have a more aggressive phenotype, which may affect cancer progression and outcome in localized tumors treated with prostatectomy. This discovery should pave the way towards future targeted therapies.
authors: Département d'oncologie médicale, Institut Curie, 26, rue d'Ulm, 75005 Paris, France. philippe.beuzeboc@curie.net
authors: P
authors: P
authors: Beuzeboc
authors: M
authors: M
authors: Soulié
authors: P
authors: P
authors: Richaud
authors: L
authors: L
authors: Salomon
authors: F
authors: F
authors: Staerman
authors: M
authors: M
authors: Peyromaure
authors: P
authors: P
authors: Mongiat-Artus
authors: F
authors: F
authors: Cornud
authors: P
authors: P
authors: Paparel
authors: J-L
authors: JL
authors: Davin
authors: V
authors: V
authors: Molinié
mesh_terms: D050939:Gene Fusion; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000628:therapy